← The Wire
PVCTOTC
PROVECTUS BIOPHARMACEUTICALS, INC.
Pharmaceutical Preparations · DE · CIK 315545
Developing immunotherapy medicines for diseases using rose bengal sodium
439
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 22, 20268-KReg FD DisclosureJun 18, 202610-Q10-QMay 14, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KCompany UpdateApr 21, 202610-K10-KMar 26, 20268-KBylaw AmendmentFeb 2, 2026SC 13DSC 13DDec 8, 202510-Q10-QNov 13, 202510-Q10-QAug 14, 20258-KShareholder VoteJun 20, 20258-KReg FD DisclosureJun 18, 2025DEFA14ADEFA14AJun 18, 202510-K/A10-K/AMay 16, 202510-Q10-QMay 14, 2025DEFA14ADEFA14AMay 1, 2025DEF 14ADEF 14AMay 1, 20258-KAuditor ChangeApr 16, 202510-K10-KMar 28, 20258-KMaterial Agreement · New Debt / ObligationJan 22, 20258-KMaterial AgreementDec 26, 20248-KCompany UpdateDec 11, 20248-KExecutive ChangeDec 5, 20248-KReg FD DisclosureNov 14, 202410-Q10-QNov 12, 20248-KExecutive ChangeAug 19, 2024SC 13GSC 13GAug 14, 202410-Q10-QAug 13, 20248-KMaterial Agreement · New Debt / ObligationJul 17, 2024SC 13DSC 13DJul 3, 20248-KMaterial Agreement · Bylaw AmendmentJun 25, 20248-KShareholder VoteJun 21, 20248-KReg FD DisclosureJun 20, 2024DEFA14ADEFA14AJun 20, 202410-Q10-QMay 14, 2024DEFA14ADEFA14AMay 6, 2024DEF 14ADEF 14AMay 6, 202410-K/A10-K/AApr 29, 20248-KExecutive Change · Reg FD DisclosureApr 16, 202410-K10-KMar 28, 20248-KMaterial Agreement · Reg FD DisclosureMar 27, 20248-KExecutive ChangeMar 26, 20248-KReg FD DisclosureFeb 22, 20248-KReg FD DisclosureFeb 15, 202410-Q10-QNov 14, 202310-Q10-QAug 14, 20238-KShareholder VoteJun 22, 20238-KReg FD DisclosureJun 21, 2023DEFA14ADEFA14AJun 21, 202310-Q10-QMay 11, 2023SC 13GSC 13GMay 9, 2023DEFA14ADEFA14AMay 1, 2023DEF 14ADEF 14AMay 1, 20238-KReg FD DisclosureApr 17, 202310-K10-KMar 30, 2023SC 13GSC 13GMar 28, 20238-KReg FD DisclosureJan 9, 20238-KCompany UpdateDec 12, 202210-Q10-QNov 9, 20228-KMaterial Agreement · New Debt / ObligationSep 26, 202210-Q10-QAug 11, 20228-KShareholder VoteJun 23, 2022DEFA14ADEFA14AJun 22, 20228-KReg FD DisclosureJun 22, 2022DEFA14ADEFA14AJun 6, 2022DEFA14ADEFA14AMay 26, 2022DEFA14ADEFA14AMay 19, 202210-Q10-QMay 12, 2022DEFA14ADEFA14AApr 29, 2022DEF 14ADEF 14AApr 29, 20228-KCompany UpdateApr 19, 20228-KBylaw AmendmentApr 5, 202210-K10-KMar 29, 202210-Q10-QNov 10, 20218-KCompany UpdateSep 7, 20218-KMaterial Agreement · New Debt / ObligationAug 18, 202110-Q10-QAug 12, 2021SC 13DSC 13DJun 30, 20218-KShareholder VoteJun 28, 2021
What Changed
Risk factors · Mar 28, 2025 → Mar 26, 202613 added · 10 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.
Newly disclosed
- Implementation of our plans and our ability to continue as a going concern will depend upon our ability to develop our prescription drug candidates and prescription drug formulation candidates, and to raise additional capital.
- Management believes that we may have access to capital resources through possible public or private equity offerings, including the 2025 Financing, exchange offers, debt financings, corporate collaborations, or other means.
- There was no restricted cash associated with the grant received from the State of Tennessee as of December 31, 2025 due to the completion of the grant award program during 2025.
- Cash balances as of December 31, 2024 included $182,284 of restricted cash associated with a grant received from the State of Tennessee.
- The Company’s working capital deficit was $6,329,503 and $5,998,712 as of December 31, 2025 and 2024, respectively.
- Moreover, we or the FDA may suspend our clinical trials at any time if it appears we are exposing participants to unacceptable health risks or if the FDA finds deficiencies in our submissions or the conduct of these trials.
- We currently intend to retain all of our future earnings, if any, for use in our business and therefore do not anticipate paying any cash dividends on our common stock in the foreseeable future.
- Accordingly, our technologies may be rendered obsolete by advances in existing technologies or the development of different technologies by one or more of our current or future competitors.
- We also expect to experience negative operating cash flow for the foreseeable future as we fund our operating losses and any future capital expenditures.
- International regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above.
- Many companies are also developing novel therapies to treat cancer and dermatological conditions and, in this regard, are our competitors.
- The Company’s cash balance was $251,291 at December 31, 2025.
No longer disclosed
- Implementation of our plans and our ability to continue as a going concern will depend upon our ability to develop our prescription drug candidates and prescription drug formulation candidates, and to raise additional capital. 13 Management believes that we may have access to capital resources through possible public or private equity offerings, including the 2025 Financing, exchange offers, debt financings, corporate collaborations, or other means.
- The Company’s cash balance was $489,726 at December 31, 2024, which includes $182,284 of restricted cash resulting from a grant received from the State of Tennessee.
- Events which may result in delays or unsuccessful completion of clinical trials, including our future clinical trials, include inability to raise funding, initiate or continue a trial, delays in obtaining regulatory approval to commence a trial, delays in reaching agreement with the FDA or other regulatory authorities on final trial design, imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities, delays in reaching agreement on acceptable terms with prospective contract research organizations and clinical trial sites, delays in obtaining required institutional review board approval at each site, delays in recruiting suitable patients to participate in a trial, delays in having subjects complete participation in a trial or return for post-treatment follow-up, delays caused by subjects dropping out of a trial, delays caused by clinical sites dropping out of a trial, time required to add new clinical sites or to obtain regulatory approval and open sites in geographic regions beyond the sites initially planned, and delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.
- The Company’s working capital deficiency was $5,998,712 and $7,652,098 as of December 31, 2024 and 2023, respectively.
- There is substantial doubt as to our ability to continue as a going concern.
- Even if we comply with all FDA requests, we cannot be sure that we will ever obtain regulatory clearance for any of our drug product candidates.
- Future sales by our stockholders may adversely affect our stock price and our ability to raise funds in new stock offerings.
- We have no sales, marketing, or distribution capabilities for our prescription drug candidates.
- If we do not update and enhance our technologies, they will become obsolete.
- Our business and operations are subject to risks related to climate change.
Similar companies
Comparable business profile · signals at a glance